Are NCCN and EAU Active Surveillance Criteria Reliable in Patients With ISUP Grade-2 Intermediate-Risk Prostate Cancer? A Novel Model Integrating MRI to Predict Adverse Pathology

Genitourinary Cancer

Predicting the indication for adjuvant radiation therapy according to EAU guidelines among patients with high-risk prostate cancer: a novel multivariable model

Prostate Cancer Prostatic Dis

Siech C, von Kriegstein H, Wenzel M, Cano Garcia C, Le QC, Tennstedt P, Preisser F, Maurer T, Kriegmair M, Chun FKH, Graefen M, Tilki D, Mandel P

doi: 10.1038/s41391-025-01018-y

Genitourinary Cancer

Long-term outcomes of active surveillance for Grade Group 1 prostate cancer and the impact of the use of MRI on overtreatment

BJU Int

de Vos II, Marenghi C, Badenchini F, Boevé ER, Lozano-Uruñuela F, Graefen M, Rannikko AS, Staerman F, Sugimoto M, Kato T, Somford DM, Frydenberg M, Bangma CH, Remmers S, Roobol MJ, Prostate Cancer Research International: Active Surveillance (PRIAS) consortium

doi: 10.1111/bju.16727

Genitourinary Cancer

Polygenic Risk Score and Upgrading in Patients With Prostate Cancer Receiving Active Surveillance

JAMA Oncol

Goss LB, Liu M, Zheng Y, Guo B, Conti DV, Haiman CA, Kachuri L, Catalona WJ, Witte JS, Lin DW, Newcomb LF, Darst BF

doi: 10.1001/jamaoncol.2024.5398

Genitourinary Cancer

Evolution of Active Surveillance of Prostate Cancer: Impact of MRI, MRI-guided Biopsy and Focal Therapy

J Urol

Martin SC, Gonzalez S, Kwan L, Delfin M, Nguyen AV, Brisbane W, Felker E, Sisk A, Priester A, Natarajan S, Marks LS

doi: 10.1097/JU.0000000000004559

Genitourinary Cancer

Does a Negative Prostate Biopsy Reduce the Risk of Prostate Cancer Reclassification in an Active Surveillance Protocol? An Updated Systematic Review and Meta-Analysis

Prostate

Bahri RA, Mohammadi A, Yar EZ, Rezayat M, Heshmat R, Aghamir SMK

doi: 10.1002/pros.24851

Genitourinary Cancer

Grade Group 1 Prostate Cancer Outcome by Biopsy Grade and Risk Group

JAMA Oncol

Patel NA, Barocas DA, Lin DW, Wu X, Green D, Kensler KH, Shoag J, Al Hussein Al Awamlh B

doi: 10.1001/jamaoncol.2025.2304

Genitourinary Cancer

Screening for Predictive Factors of Efficacy of Second-Generation Androgen Receptor Axis-Targeted Agents in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer

Prostate

Ueda T, Hayakawa K, Horiguchi G, Murashita J, Shiraishi T, Fujimoto S, Miyashita M, Saito Y, Gabata Y, Sako S, Takahashi H, Fujihara A, Minami T, Yamamoto Y, Okumi M, Hongo F, Okihara K, Fujita K, Ukimura O

doi: 10.1002/pros.24855

Genitourinary Cancer

Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials

J Clin Oncol

Armstrong AJ, Liu VYT, Selvaraju RR, Chen E, Simko JP, DeVries S, Sartor O, Sandler HM, Mohamad O, Huang HC, Griffin J, Yamashita R, Esteva A, Tran PT, Spratt DE, Carson JH, Peters C, Gore E, Lee SP, Monson JM, Augspurger ME, El-Gayed A, Rodgers JP, McKay R, Morgan T, Feng FY, Nguyen PL

doi: 10.1200/JCO.24.00365

Genitourinary Cancer

Evolving Risk of Urinary Adverse Events Across Localized Prostate Cancer Treatments: A Propensity-weighted Analysis of Surveillance, Epidemiology and End Results-Medicare Data

Eur Urol

Li KD, Carlisle MN, Jarosek S, Patel HV, Faris A, Elliott SP, Cooperberg MR, Carroll PR, Breyer BN

doi: 10.1016/j.eururo.2025.05.014

Related content

Predicting the indication for adjuvant radiation therapy according to EAU guidelines among patients with high-risk prostate cancer: a novel multivariable model

Long-term outcomes of active surveillance for Grade Group 1 prostate cancer and the impact of the use of MRI on overtreatment

Polygenic Risk Score and Upgrading in Patients With Prostate Cancer Receiving Active Surveillance

Evolution of Active Surveillance of Prostate Cancer: Impact of MRI, MRI-guided Biopsy and Focal Therapy

Does a Negative Prostate Biopsy Reduce the Risk of Prostate Cancer Reclassification in an Active Surveillance Protocol? An Updated Systematic Review and Meta-Analysis

Grade Group 1 Prostate Cancer Outcome by Biopsy Grade and Risk Group

Screening for Predictive Factors of Efficacy of Second-Generation Androgen Receptor Axis-Targeted Agents in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer

Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials

Evolving Risk of Urinary Adverse Events Across Localized Prostate Cancer Treatments: A Propensity-weighted Analysis of Surveillance, Epidemiology and End Results-Medicare Data